Does Rallies show 13F holders for XLO?

Yes. Rallies tracks hedge fund and 13F ownership data for XLO, including fund names, share counts, latest tracked quarter, and position changes when available.

Is XLO research on Rallies investment advice?

No. Rallies provides research, data, and educational context for XLO. It does not provide personalized investment advice.

XLO (Xilio Therapeutics, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Xilio Therapeutics, Inc. Common Stock (XLO) is a publicly traded Healthcare sector company. As of May 21, 2026, XLO trades at $8.44 with a market cap of $48.76M and a P/E ratio of -1.97. XLO moved +1.83% today. Year to date, XLO is -10.87%; over the trailing twelve months it is -32.88%. Its 52-week range spans $6.47 to $23.80. Rallies surfaces XLO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns XLO stock?

Hedge funds tracked by Rallies that own XLO include Renaissance Technologies, Two Sigma, Citadel Advisors, and Two Sigma. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Xilio Therapeutics, Inc. Common Stock.

XLO Key Metrics

Key financial metrics for XLO
Metric	Value
Price	$8.44
Market Cap	$48.76M
P/E Ratio	-1.97
EPS	$-4.19
Dividend Yield	0.00%
52-Week High	$23.80
52-Week Low	$6.47
Volume	0
Avg Volume	0
Revenue (TTM)	$43.77M
Net Income	$-35.04M
Gross Margin	0.00%

Top Hedge Funds Holding XLO

Renaissance Technologies holds 296.62K shares of XLO, changed +11.38% as of Dec 31, 2024.
Two Sigma holds 44.45K shares of XLO, changed +234.90% as of Sep 30, 2024.
Citadel Advisors holds 40.32K shares of XLO, changed -21.59% as of Dec 31, 2024.
Two Sigma holds 10.82K shares of XLO, changed +4.19% as of Dec 31, 2024.

Latest XLO News

Xilio Therapeutics Extends Runway to 2028, Plans XTX501 IND in Mid-2026 — May 12, 2026
Xilio Therapeutics Plans 1-for-14 Reverse Split to Cut Shares to 5.2M — Mar 12, 2026
Xilio Therapeutics Raises $40M with 74.8M Pre-Funded Warrants at $0.5349 — Feb 12, 2026

Recent XLO Insider Trades

Shannon James Samuel bought 5.00K (~$43.95K) on Mar 26, 2026.
Brennan Kevin M. sold 1.83K (~$1.17K) on Jan 2, 2026.
Frankenfield Christopher James sold 7.03K (~$4.52K) on Jan 2, 2026.

XLO Analyst Consensus

XLO analyst coverage data. Average price target: $0.00.

Common questions about XLO

Who owns XLO stock?: Hedge funds tracked by Rallies that own XLO include Renaissance Technologies, Two Sigma, Citadel Advisors, and Two Sigma. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Xilio Therapeutics, Inc. Common Stock.
Does Rallies show 13F holders for XLO?: Yes. Rallies tracks hedge fund and 13F ownership data for XLO, including fund names, share counts, latest tracked quarter, and position changes when available.
Is XLO research on Rallies investment advice?: No. Rallies provides research, data, and educational context for XLO. It does not provide personalized investment advice.